ID   WWP2_HUMAN              Reviewed;         870 AA.
AC   O00308; A6NEP1; B2R706; B4DTL5; F5H213; H3BRF3; I3RSG8; Q6ZTQ5;
AC   Q96CZ2; Q9BWN6;
DT   20-JUN-2003, integrated into UniProtKB/Swiss-Prot.
DT   20-JUN-2003, sequence version 2.
DT   15-MAR-2017, entry version 167.
DE   RecName: Full=NEDD4-like E3 ubiquitin-protein ligase WWP2;
DE            EC=2.3.2.26 {ECO:0000269|PubMed:19274063, ECO:0000269|PubMed:19651900};
DE   AltName: Full=Atrophin-1-interacting protein 2;
DE            Short=AIP2;
DE   AltName: Full=HECT-type E3 ubiquitin transferase WWP2;
DE   AltName: Full=WW domain-containing protein 2;
GN   Name=WWP2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND INTERACTION WITH WBP1;
RP   WBP2; SCNN1A; SCNN1B AND SCNN1G.
RC   TISSUE=Bone marrow, and Brain;
RX   PubMed=9169421; DOI=10.1074/jbc.272.23.14611;
RA   Pirozzi G., McConnell S.J., Uveges A.J., Carter J.M., Sparks A.B.,
RA   Kay B.K., Fowlkes D.M.;
RT   "Identification of novel human WW domain-containing proteins by
RT   cloning of ligand targets.";
RL   J. Biol. Chem. 272:14611-14616(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Jiang G.Y., Yang J.H., Liu S.F.;
RT   "Bioinformatic analysis of E3 ligase WWP2 in 14 different
RT   vertebrates.";
RL   Submitted (SEP-2011) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Placenta, Testis, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15616553; DOI=10.1038/nature03187;
RA   Martin J., Han C., Gordon L.A., Terry A., Prabhakar S., She X.,
RA   Xie G., Hellsten U., Chan Y.M., Altherr M., Couronne O., Aerts A.,
RA   Bajorek E., Black S., Blumer H., Branscomb E., Brown N.C., Bruno W.J.,
RA   Buckingham J.M., Callen D.F., Campbell C.S., Campbell M.L.,
RA   Campbell E.W., Caoile C., Challacombe J.F., Chasteen L.A.,
RA   Chertkov O., Chi H.C., Christensen M., Clark L.M., Cohn J.D.,
RA   Denys M., Detter J.C., Dickson M., Dimitrijevic-Bussod M., Escobar J.,
RA   Fawcett J.J., Flowers D., Fotopulos D., Glavina T., Gomez M.,
RA   Gonzales E., Goodstein D., Goodwin L.A., Grady D.L., Grigoriev I.,
RA   Groza M., Hammon N., Hawkins T., Haydu L., Hildebrand C.E., Huang W.,
RA   Israni S., Jett J., Jewett P.B., Kadner K., Kimball H., Kobayashi A.,
RA   Krawczyk M.-C., Leyba T., Longmire J.L., Lopez F., Lou Y., Lowry S.,
RA   Ludeman T., Manohar C.F., Mark G.A., McMurray K.L., Meincke L.J.,
RA   Morgan J., Moyzis R.K., Mundt M.O., Munk A.C., Nandkeshwar R.D.,
RA   Pitluck S., Pollard M., Predki P., Parson-Quintana B., Ramirez L.,
RA   Rash S., Retterer J., Ricke D.O., Robinson D.L., Rodriguez A.,
RA   Salamov A., Saunders E.H., Scott D., Shough T., Stallings R.L.,
RA   Stalvey M., Sutherland R.D., Tapia R., Tesmer J.G., Thayer N.,
RA   Thompson L.S., Tice H., Torney D.C., Tran-Gyamfi M., Tsai M.,
RA   Ulanovsky L.E., Ustaszewska A., Vo N., White P.S., Williams A.L.,
RA   Wills P.L., Wu J.-R., Wu K., Yang J., DeJong P., Bruce D.,
RA   Doggett N.A., Deaven L., Schmutz J., Grimwood J., Richardson P.,
RA   Rokhsar D.S., Eichler E.E., Gilna P., Lucas S.M., Myers R.M.,
RA   Rubin E.M., Pennacchio L.A.;
RT   "The sequence and analysis of duplication-rich human chromosome 16.";
RL   Nature 432:988-994(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 4).
RC   TISSUE=Brain, Ovary, and Placenta;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   INTERACTION WITH ATN1, AND TISSUE SPECIFICITY.
RX   PubMed=9647693; DOI=10.1006/mcne.1998.0677;
RA   Wood J.D., Yuan J., Margolis R.L., Colomer V., Duan K., Kushi J.,
RA   Kaminsky Z., Kleiderlein J.J. Jr., Sharp A.H., Ross C.A.;
RT   "Atrophin-1, the DRPLA gene product, interacts with two families of WW
RT   domain-containing proteins.";
RL   Mol. Cell. Neurosci. 11:149-160(1998).
RN   [8]
RP   INTERACTION WITH SCNN1A; SCNN1B AND SCNN1G.
RX   PubMed=12167593; DOI=10.1152/ajprenal.00080.2002;
RA   McDonald F.J., Western A.H., McNeil J.D., Thomas B.C., Olson D.R.,
RA   Snyder P.M.;
RT   "Ubiquitin-protein ligase WWP2 binds to and downregulates the
RT   epithelial Na(+) channel.";
RL   Am. J. Physiol. 283:F431-F436(2002).
RN   [9]
RP   INTERACTION WITH ADENOVIRUS TYPE 2 PIII.
RX   PubMed=12450395; DOI=10.1021/bi020125b;
RA   Galinier R., Gout E., Lortat-Jacob H., Wood J., Chroboczek J.;
RT   "Adenovirus protein involved in virus internalization recruits
RT   ubiquitin-protein ligases.";
RL   Biochemistry 41:14299-14305(2002).
RN   [10]
RP   INTERACTION WITH NDFIP1.
RX   PubMed=11748237; DOI=10.1074/jbc.M110443200;
RA   Harvey K.F., Shearwin-Whyatt L.M., Fotia A., Parton R.G., Kumar S.;
RT   "N4WBP5, a potential target for ubiquitination by the Nedd4 family of
RT   proteins, is a novel Golgi-associated protein.";
RL   J. Biol. Chem. 277:9307-9317(2002).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [12]
RP   AUTOINHIBITION BY C2 DOMAIN.
RX   PubMed=17719543; DOI=10.1016/j.cell.2007.06.050;
RA   Wiesner S., Ogunjimi A.A., Wang H.R., Rotin D., Sicheri F.,
RA   Wrana J.L., Forman-Kay J.D.;
RT   "Autoinhibition of the HECT-type ubiquitin ligase Smurf2 through its
RT   C2 domain.";
RL   Cell 130:651-662(2007).
RN   [13]
RP   FUNCTION IN UBIQUITINATION OF POU5F1, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DEVELOPMENTAL STAGE, INTERACTION WITH POU5F1, AND
RP   MUTAGENESIS OF CYS-838.
RX   PubMed=19274063; DOI=10.1038/cr.2009.31;
RA   Xu H., Wang W., Li C., Yu H., Yang A., Wang B., Jin Y.;
RT   "WWP2 promotes degradation of transcription factor OCT4 in human
RT   embryonic stem cells.";
RL   Cell Res. 19:561-573(2009).
RN   [14]
RP   ACTIVATION BY NDFIP1 AND NDFIP2, AND AUTOUBIQUITINATION.
RX   PubMed=19343052; DOI=10.1038/embor.2009.30;
RA   Mund T., Pelham H.R.;
RT   "Control of the activity of WW-HECT domain E3 ubiquitin ligases by
RT   NDFIP proteins.";
RL   EMBO Rep. 10:501-507(2009).
RN   [15]
RP   FUNCTION IN UBIQUITINATION OF EGR2, AND INTERACTION WITH EGR2.
RX   PubMed=19651900; DOI=10.1128/MCB.00407-09;
RA   Chen A., Gao B., Zhang J., McEwen T., Ye S.Q., Zhang D., Fang D.;
RT   "The HECT-type E3 ubiquitin ligase AIP2 inhibits activation-induced T-
RT   cell death by catalyzing EGR2 ubiquitination.";
RL   Mol. Cell. Biol. 29:5348-5356(2009).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY, INTERACTION WITH ERBB4, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=20858735; DOI=10.1158/1541-7786.MCR-10-0042;
RA   Gilmore-Hebert M., Ramabhadran R., Stern D.F.;
RT   "Interactions of ErbB4 and Kap1 connect the growth factor and DNA
RT   damage response pathways.";
RL   Mol. Cancer Res. 8:1388-1398(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [18]
RP   UBIQUITINATION, AND MUTAGENESIS OF LYS-498 AND HIS-500.
RX   PubMed=21572392; DOI=10.1038/emboj.2011.155;
RA   Cui Y., He S., Xing C., Lu K., Wang J., Xing G., Meng A., Jia S.,
RA   He F., Zhang L.;
RT   "SCF(FBXL15) regulates BMP signalling by directing the degradation of
RT   HECT-type ubiquitin ligase Smurf1.";
RL   EMBO J. 30:2675-2689(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   INTERACTION WITH ARRDC4.
RX   PubMed=23236378; DOI=10.1371/journal.pone.0050557;
RA   Shea F.F., Rowell J.L., Li Y., Chang T.H., Alvarez C.E.;
RT   "Mammalian alpha arrestins link activated seven transmembrane
RT   receptors to Nedd4 family e3 ubiquitin ligases and interact with beta
RT   arrestins.";
RL   PLoS ONE 7:E50557-E50557(2012).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-211, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.51 ANGSTROMS) OF 492-865.
RX   PubMed=26457515; DOI=10.1107/S2053230X1501554X;
RA   Gong W., Zhang X., Zhang W., Li J., Li Z.;
RT   "Structure of the HECT domain of human WWP2.";
RL   Acta Crystallogr. F 71:1251-1257(2015).
CC   -!- FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from
CC       an E2 ubiquitin-conjugating enzyme in the form of a thioester and
CC       then directly transfers the ubiquitin to targeted substrates.
CC       Polyubiquitinates POU5F1 by 'Lys-63'-linked conjugation and
CC       promotes it to proteasomal degradation; in embryonic stem cells
CC       (ESCs) the ubiquitination is proposed to regulate POU5F1 protein
CC       level. Ubiquitinates EGR2 and promotes it to proteasomal
CC       degradation; in T-cells the ubiquitination inhibits activation-
CC       induced cell death. Ubiquitinates SLC11A2; the ubiquitination is
CC       enhanced by presence of NDFIP1 and NDFIP2. Ubiquitinates RPB1 and
CC       promotes it to proteasomal degradation.
CC       {ECO:0000269|PubMed:19274063, ECO:0000269|PubMed:19651900}.
CC   -!- CATALYTIC ACTIVITY: S-ubiquitinyl-[E2 ubiquitin-conjugating
CC       enzyme]-L-cysteine + [acceptor protein]-L-lysine = [E2 ubiquitin-
CC       conjugating enzyme]-L-cysteine + N(6)-ubiquitinyl-[acceptor
CC       protein]-L-lysine. {ECO:0000269|PubMed:19274063,
CC       ECO:0000269|PubMed:19651900}.
CC   -!- ENZYME REGULATION: Activated by NDFIP1- and NDFIP2-binding.
CC       {ECO:0000269|PubMed:19343052}.
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC       {ECO:0000269|PubMed:19274063, ECO:0000269|PubMed:19651900}.
CC   -!- SUBUNIT: Interacts with POU5F1, RBP1, EGR2 and SLC11A2 (By
CC       similarity). Interacts with SCNN1A, SCNN1B, SCNN1G, WBP1, WBP2,
CC       ATN1 and adenovirus type 2 PIII. Interacts with ERBB4, NDFIP1 AND
CC       NDFIP2. Interacts with ARRDC4 (PubMed:23236378).
CC       {ECO:0000250|UniProtKB:Q9DBH0, ECO:0000269|PubMed:11748237,
CC       ECO:0000269|PubMed:12167593, ECO:0000269|PubMed:12450395,
CC       ECO:0000269|PubMed:19274063, ECO:0000269|PubMed:19651900,
CC       ECO:0000269|PubMed:20858735, ECO:0000269|PubMed:23236378,
CC       ECO:0000269|PubMed:9169421, ECO:0000269|PubMed:9647693}.
CC   -!- INTERACTION:
CC       Q8WU02:-; NbExp=3; IntAct=EBI-743923, EBI-747182;
CC       P78563:ADARB1; NbExp=5; IntAct=EBI-743923, EBI-2967304;
CC       Q8N8A2:ANKRD44; NbExp=3; IntAct=EBI-743923, EBI-1245329;
CC       Q8N5I2:ARRDC1; NbExp=3; IntAct=EBI-743923, EBI-2339564;
CC       Q96B67:ARRDC3; NbExp=4; IntAct=EBI-743923, EBI-2875665;
CC       Q96D16:FBXL18; NbExp=3; IntAct=EBI-743923, EBI-744419;
CC       Q9BUJ2:HNRNPUL1; NbExp=6; IntAct=EBI-743923, EBI-1018153;
CC       Q3B8N2:LGALS9B; NbExp=3; IntAct=EBI-743923, EBI-10240775;
CC       Q9NR12:PDLIM7; NbExp=4; IntAct=EBI-743923, EBI-350517;
CC       Q01860:POU5F1; NbExp=4; IntAct=EBI-743923, EBI-475687;
CC       Q9BVN2:RUSC1; NbExp=3; IntAct=EBI-743923, EBI-6257312;
CC       Q15796:SMAD2; NbExp=4; IntAct=EBI-743923, EBI-1040141;
CC       P84022:SMAD3; NbExp=7; IntAct=EBI-743923, EBI-347161;
CC       O15105:SMAD7; NbExp=5; IntAct=EBI-743923, EBI-3861591;
CC       Q5TAL4:SNRPC; NbExp=3; IntAct=EBI-743923, EBI-10246938;
CC       Q9BUZ4:TRAF4; NbExp=6; IntAct=EBI-743923, EBI-3650647;
CC       A5D8V6:VPS37C; NbExp=5; IntAct=EBI-743923, EBI-2559305;
CC       O43516:WIPF1; NbExp=4; IntAct=EBI-743923, EBI-346356;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:19274063,
CC       ECO:0000269|PubMed:20858735}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=O00308-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00308-2; Sequence=VSP_044706;
CC         Note=No experimental confirmation available.;
CC       Name=3;
CC         IsoId=O00308-3; Sequence=VSP_046461;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=O00308-4; Sequence=VSP_054711;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Detected in heart, throughout the brain,
CC       placenta, lung, liver, muscle, kidney and pancreas. Also detected
CC       in spleen and peripheral blood leukocytes.
CC       {ECO:0000269|PubMed:19274063, ECO:0000269|PubMed:9647693}.
CC   -!- DEVELOPMENTAL STAGE: Highly expressed in undifferentiated
CC       embryonic stem cells and expression is reduced after embryoid body
CC       (EB) formation. Not detectable at day 13 of EB formation; low
CC       levels are again detected at day 18 of EB formation.
CC       {ECO:0000269|PubMed:19274063}.
CC   -!- DOMAIN: The C2 domain is involved in autoinhibition of the
CC       catalytic activity by interacting with the HECT domain.
CC       {ECO:0000250}.
CC   -!- PTM: Autoubiquitinated. Ubiquitinated by the SCF(FBXL15) complex,
CC       leading to its degradation by the proteasome.
CC       {ECO:0000269|PubMed:19343052, ECO:0000269|PubMed:21572392}.
CC   -!- MISCELLANEOUS: A cysteine residue is required for ubiquitin-
CC       thioester formation.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC86528.1; Type=Frameshift; Positions=757; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; U96114; AAC51325.1; -; mRNA.
DR   EMBL; JN712744; AFK29253.1; -; mRNA.
DR   EMBL; AK126332; BAC86528.1; ALT_FRAME; mRNA.
DR   EMBL; AK300266; BAG62027.1; -; mRNA.
DR   EMBL; AK312792; BAG35653.1; -; mRNA.
DR   EMBL; AC026468; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC092115; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471092; EAW83287.1; -; Genomic_DNA.
DR   EMBL; BC000108; AAH00108.1; -; mRNA.
DR   EMBL; BC013645; AAH13645.1; -; mRNA.
DR   EMBL; BC064531; AAH64531.1; -; mRNA.
DR   CCDS; CCDS10885.1; -. [O00308-1]
DR   CCDS; CCDS58475.1; -. [O00308-4]
DR   CCDS; CCDS58476.1; -. [O00308-2]
DR   CCDS; CCDS58477.1; -. [O00308-3]
DR   RefSeq; NP_001257382.1; NM_001270453.1. [O00308-2]
DR   RefSeq; NP_001257383.1; NM_001270454.1. [O00308-1]
DR   RefSeq; NP_001257384.1; NM_001270455.1. [O00308-4]
DR   RefSeq; NP_008945.2; NM_007014.4. [O00308-1]
DR   RefSeq; NP_955456.1; NM_199424.2. [O00308-3]
DR   RefSeq; XP_011521125.1; XM_011522823.2. [O00308-1]
DR   RefSeq; XP_011521127.1; XM_011522825.1. [O00308-1]
DR   RefSeq; XP_011521128.1; XM_011522826.2. [O00308-2]
DR   RefSeq; XP_016878368.1; XM_017022879.1. [O00308-1]
DR   RefSeq; XP_016878369.1; XM_017022880.1. [O00308-1]
DR   RefSeq; XP_016878370.1; XM_017022881.1. [O00308-1]
DR   UniGene; Hs.408458; -.
DR   PDB; 4Y07; X-ray; 2.51 A; A=492-865.
DR   PDBsum; 4Y07; -.
DR   ProteinModelPortal; O00308; -.
DR   SMR; O00308; -.
DR   BioGrid; 116244; 98.
DR   IntAct; O00308; 68.
DR   MINT; MINT-148449; -.
DR   STRING; 9606.ENSP00000348283; -.
DR   iPTMnet; O00308; -.
DR   PhosphoSitePlus; O00308; -.
DR   BioMuta; WWP2; -.
DR   EPD; O00308; -.
DR   MaxQB; O00308; -.
DR   PaxDb; O00308; -.
DR   PeptideAtlas; O00308; -.
DR   PRIDE; O00308; -.
DR   DNASU; 11060; -.
DR   Ensembl; ENST00000356003; ENSP00000348283; ENSG00000198373. [O00308-2]
DR   Ensembl; ENST00000359154; ENSP00000352069; ENSG00000198373. [O00308-1]
DR   Ensembl; ENST00000568684; ENSP00000456216; ENSG00000198373. [O00308-3]
DR   Ensembl; ENST00000569174; ENSP00000455311; ENSG00000198373. [O00308-4]
DR   GeneID; 11060; -.
DR   KEGG; hsa:11060; -.
DR   UCSC; uc002exv.3; human. [O00308-1]
DR   CTD; 11060; -.
DR   DisGeNET; 11060; -.
DR   GeneCards; WWP2; -.
DR   HGNC; HGNC:16804; WWP2.
DR   MIM; 602308; gene.
DR   neXtProt; NX_O00308; -.
DR   OpenTargets; ENSG00000198373; -.
DR   PharmGKB; PA134946925; -.
DR   eggNOG; KOG0940; Eukaryota.
DR   eggNOG; COG5021; LUCA.
DR   GeneTree; ENSGT00760000118966; -.
DR   HOGENOM; HOG000208453; -.
DR   HOVERGEN; HBG004134; -.
DR   InParanoid; O00308; -.
DR   KO; K05630; -.
DR   OMA; PENRHQP; -.
DR   OrthoDB; EOG091G0SS8; -.
DR   PhylomeDB; O00308; -.
DR   TreeFam; TF323658; -.
DR   BRENDA; 2.3.2.B9; 2681.
DR   SignaLink; O00308; -.
DR   UniPathway; UPA00143; -.
DR   ChiTaRS; WWP2; human.
DR   GeneWiki; WWP2; -.
DR   GenomeRNAi; 11060; -.
DR   PRO; PR:O00308; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   Bgee; ENSG00000198373; -.
DR   CleanEx; HS_WWP2; -.
DR   ExpressionAtlas; O00308; baseline and differential.
DR   Genevisible; O00308; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:BHF-UCL.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000151; C:ubiquitin ligase complex; TAS:ProtInc.
DR   GO; GO:0001085; F:RNA polymerase II transcription factor binding; IPI:BHF-UCL.
DR   GO; GO:0008134; F:transcription factor binding; IPI:UniProtKB.
DR   GO; GO:0001190; F:transcriptional activator activity, RNA polymerase II transcription factor binding; IEA:Ensembl.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IEA:Ensembl.
DR   GO; GO:0004842; F:ubiquitin-protein transferase activity; IDA:UniProtKB.
DR   GO; GO:0006464; P:cellular protein modification process; TAS:ProtInc.
DR   GO; GO:0010629; P:negative regulation of gene expression; IMP:UniProtKB.
DR   GO; GO:0051224; P:negative regulation of protein transport; IMP:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; ISS:BHF-UCL.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IMP:BHF-UCL.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; ISS:BHF-UCL.
DR   GO; GO:0032410; P:negative regulation of transporter activity; IDA:UniProtKB.
DR   GO; GO:0043161; P:proteasome-mediated ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0051865; P:protein autoubiquitination; IDA:FlyBase.
DR   GO; GO:0070534; P:protein K63-linked ubiquitination; ISS:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0042391; P:regulation of membrane potential; IDA:BHF-UCL.
DR   GO; GO:1901016; P:regulation of potassium ion transmembrane transporter activity; IDA:BHF-UCL.
DR   GO; GO:0046718; P:viral entry into host cell; TAS:UniProtKB.
DR   CDD; cd00078; HECTc; 1.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR024928; E3_ub_ligase_SMURF1.
DR   InterPro; IPR000569; HECT_dom.
DR   InterPro; IPR001202; WW_dom.
DR   Pfam; PF00632; HECT; 1.
DR   Pfam; PF00397; WW; 4.
DR   PIRSF; PIRSF001569; E3_ub_ligase_SMURF1; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00119; HECTc; 1.
DR   SMART; SM00456; WW; 4.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF51045; SSF51045; 4.
DR   SUPFAM; SSF56204; SSF56204; 1.
DR   PROSITE; PS50237; HECT; 1.
DR   PROSITE; PS01159; WW_DOMAIN_1; 4.
DR   PROSITE; PS50020; WW_DOMAIN_2; 4.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Complete proteome;
KW   Host-virus interaction; Nucleus; Phosphoprotein; Reference proteome;
KW   Repeat; Transferase; Ubl conjugation; Ubl conjugation pathway.
FT   CHAIN         1    870       NEDD4-like E3 ubiquitin-protein ligase
FT                                WWP2.
FT                                /FTId=PRO_0000120338.
FT   DOMAIN       20    100       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      300    333       WW 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      330    363       WW 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      405    437       WW 3. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      444    477       WW 4. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00224}.
FT   DOMAIN      536    870       HECT. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00104}.
FT   ACT_SITE    838    838       Glycyl thioester intermediate.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00104}.
FT   MOD_RES     211    211       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   VAR_SEQ       1    439       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046461.
FT   VAR_SEQ       1    116       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_044706.
FT   VAR_SEQ     336    870       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_054711.
FT   MUTAGEN     498    498       K->R: Does not affect FBXL15-mediated
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:21572392}.
FT   MUTAGEN     500    500       H->K: Does not affect FBXL15-mediated
FT                                ubiquitination.
FT                                {ECO:0000269|PubMed:21572392}.
FT   MUTAGEN     838    838       C->A: Abolishes ubiquitination of POU5F1.
FT                                {ECO:0000269|PubMed:19274063}.
FT   CONFLICT    136    136       E -> K (in Ref. 1; AAC51325).
FT                                {ECO:0000305}.
FT   CONFLICT    390    390       F -> L (in Ref. 3; BAG62027).
FT                                {ECO:0000305}.
FT   CONFLICT    394    395       SS -> FW (in Ref. 1; AAC51325).
FT                                {ECO:0000305}.
FT   CONFLICT    545    545       Y -> F (in Ref. 3; BAC86528).
FT                                {ECO:0000305}.
FT   HELIX       495    508       {ECO:0000244|PDB:4Y07}.
FT   STRAND      512    519       {ECO:0000244|PDB:4Y07}.
FT   HELIX       524    533       {ECO:0000244|PDB:4Y07}.
FT   HELIX       537    541       {ECO:0000244|PDB:4Y07}.
FT   STRAND      542    548       {ECO:0000244|PDB:4Y07}.
FT   HELIX       556    570       {ECO:0000244|PDB:4Y07}.
FT   TURN        574    577       {ECO:0000244|PDB:4Y07}.
FT   STRAND      578    583       {ECO:0000244|PDB:4Y07}.
FT   TURN        584    586       {ECO:0000244|PDB:4Y07}.
FT   STRAND      587    591       {ECO:0000244|PDB:4Y07}.
FT   HELIX       593    597       {ECO:0000244|PDB:4Y07}.
FT   HELIX       601    617       {ECO:0000244|PDB:4Y07}.
FT   HELIX       628    634       {ECO:0000244|PDB:4Y07}.
FT   HELIX       641    647       {ECO:0000244|PDB:4Y07}.
FT   HELIX       649    660       {ECO:0000244|PDB:4Y07}.
FT   HELIX       704    714       {ECO:0000244|PDB:4Y07}.
FT   HELIX       718    731       {ECO:0000244|PDB:4Y07}.
FT   HELIX       734    737       {ECO:0000244|PDB:4Y07}.
FT   HELIX       742    750       {ECO:0000244|PDB:4Y07}.
FT   HELIX       757    762       {ECO:0000244|PDB:4Y07}.
FT   STRAND      765    768       {ECO:0000244|PDB:4Y07}.
FT   HELIX       774    785       {ECO:0000244|PDB:4Y07}.
FT   HELIX       788    799       {ECO:0000244|PDB:4Y07}.
FT   HELIX       809    811       {ECO:0000244|PDB:4Y07}.
FT   STRAND      822    824       {ECO:0000244|PDB:4Y07}.
FT   STRAND      834    836       {ECO:0000244|PDB:4Y07}.
FT   TURN        837    840       {ECO:0000244|PDB:4Y07}.
FT   STRAND      841    843       {ECO:0000244|PDB:4Y07}.
FT   HELIX       850    863       {ECO:0000244|PDB:4Y07}.
SQ   SEQUENCE   870 AA;  98912 MW;  FCCD75CBA61F2204 CRC64;
     MASASSSRAG VALPFEKSQL TLKVVSAKPK VHNRQPRINS YVEVAVDGLP SETKKTGKRI
     GSSELLWNEI IILNVTAQSH LDLKVWSCHT LRNELLGTAS VNLSNVLKNN GGKMENMQLT
     LNLQTENKGS VVSGGELTIF LDGPTVDLGN VPNGSALTDG SQLPSRDSSG TAVAPENRHQ
     PPSTNCFGGR SRTHRHSGAS ARTTPATGEQ SPGARSRHRQ PVKNSGHSGL ANGTVNDEPT
     TATDPEEPSV VGVTSPPAAP LSVTPNPNTT SLPAPATPAE GEEPSTSGTQ QLPAAAQAPD
     ALPAGWEQRE LPNGRVYYVD HNTKTTTWER PLPPGWEKRT DPRGRFYYVD HNTRTTTWQR
     PTAEYVRNYE QWQSQRNQLQ GAMQHFSQRF LYQSSSASTD HDPLGPLPPG WEKRQDNGRV
     YYVNHNTRTT QWEDPRTQGM IQEPALPPGW EMKYTSEGVR YFVDHNTRTT TFKDPRPGFE
     SGTKQGSPGA YDRSFRWKYH QFRFLCHSNA LPSHVKISVS RQTLFEDSFQ QIMNMKPYDL
     RRRLYIIMRG EEGLDYGGIA REWFFLLSHE VLNPMYCLFE YAGKNNYCLQ INPASSINPD
     HLTYFRFIGR FIAMALYHGK FIDTGFTLPF YKRMLNKRPT LKDLESIDPE FYNSIVWIKE
     NNLEECGLEL YFIQDMEILG KVTTHELKEG GESIRVTEEN KEEYIMLLTD WRFTRGVEEQ
     TKAFLDGFNE VAPLEWLRYF DEKELELMLC GMQEIDMSDW QKSTIYRHYT KNSKQIQWFW
     QVVKEMDNEK RIRLLQFVTG TCRLPVGGFA ELIGSNGPQK FCIDKVGKET WLPRSHTCFN
     RLDLPPYKSY EQLREKLLYA IEETEGFGQE
//
